ArticleInternational journal of hematology2020
Immune thrombocytopenia in a patient with COVID-19.
Article in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- SARS-CoV-2 infection-induced immune thrombocytopenia: a systematic review of current reports.Annals of hematology · 2024Pooled it
- The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 - A systematic review of the literature.Journal of autoimmunity · 2021Pooled it
- Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review.Frontiers in immunologyPooled it
- Persistent Immune Thrombocytopenia as a Post-Acute Sequelae of COVID-19: A Case Report.Public health challenges · 2026Article
- Linezolid-Associated Thrombocytopenia: Assessment of Risk Factors in Patients without Hemato-Oncologic Diseases.Journal of clinical medicine · 2024Article
- Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study.EClinicalMedicine · 2023Article
- COVID-19 and Subsequent Development of Pancytopenia With Concurrent Disseminated Intravascular Coagulation.Cureus · 2022Article
- Can SARS-CoV-2 trigger new onset of autoimmune disease in adults? A case-based review.Heliyon · 2022Review
- Experience of danaparoid to treat vaccine-induced immune thrombocytopenia and thrombosis, VITT.Thrombosis journal · 2022Article
- COVID-19-A Trigger Factor for Severe Immune-Mediated Thrombocytopenia in Active Rheumatoid Arthritis.Life (Basel, Switzerland) · 2022Article
- Immune thrombocytopenia in a child with COVID-19: Is it the calm after the (cytokine) storm?Pediatric blood & cancer · 2022Article
- A review of ischemic stroke in COVID-19: currently known pathophysiological mechanisms.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Review
- Do we miss rare adverse events induced by COVID-19 vaccination?Frontiers in medicine · 2022Review
- A full-term pregnant woman with secondary Evans syndrome caused by severe coronavirus disease 2019: a case report.Journal of medical case reports · 2021Article
- SARS-CoV-2 and Plasma Hypercoagulability.Cellular and molecular bioengineering · 2021Review
- Platelets in the perspective of COVID-19; pathophysiology of thrombocytopenia and its implication as prognostic and therapeutic opportunity.International immunopharmacology · 2021Review
- Article
- Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination.Thrombosis research · 2021Article
- Evans syndrome and immune thrombocytopenia in two patients with COVID-19.Journal of medical virology · 2021Article
- Delayed onset of severe immune thrombocytopenia associated with COVID-19 pneumonia.Respiratory medicine case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report describes immune thrombocytopenic purpura in a 41-year-old man hospitalized in the intensive-care unit for COVID-19, 13 days after the onset of COVID-19 symptoms with respiratory failure at admission. Acute respiratory distress syndrome was treated with, among other drugs, low-molecular-weight heparin. On day 8, his platelet count began descending rapidly. On day 10, heparin treatment was replaced by danaparoid sodium, but by day 13, the continued low platelet count made a diagnosis of heparin-induced thrombocytopenia unlikely. Normocytic nonregenerative anemia gradually developed. On day 13, a bone marrow aspiration showed numerous megakaryocytes and a few signs of hemophagocytosis. Corticosteroids were introduced on day 14, and platelets began rising after 3 days and then fell again on day 19. Intravenous immunoglobulin (IV Ig) was then administered. Two days later, the platelet count returned to normal. The immune cause was confirmed by ruling out the differential diagnoses and the excellent and rapid response to intravenous immunoglobulins. Finally, the patient's respiratory state improved. He was discharged to a respiratory rehabilitation unit on day 38. Our case suggests that an immunological cause should be considered in patients with thrombocytopenia during COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.